2009;150:551 555. of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588 597. Meschia et al Guidelines for the Primary Prevention of Stroke 3817 369. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health. 2009;19:650 654. 370. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrilla- tion. Med Clin North Am. 2008;92:17 40, ix. 371. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983 988. 372. Stroke Risk in Atrial Fibrillation Working Group. Independent predic- tors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546 554. 373. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901 1910. 374. Benjamin EJ, Wolf PA, D Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946 952. 375. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115 1119. 376. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GY, Allan TF. Screening versus rou- tine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007;335:383. 377. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost- effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study. Health Technol Assess. 2005;9:iii-iv, ix-x, 1 74. 378. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864 2870. 379. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263 272. 380. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, GoAS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e531S 575S. 381. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093 1100. 382. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES,ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) study. J Am Coll Cardiol. 2012;60:861 867. 383. Taillandier S, Olesen JB, Clementy N, Lagrenade I, Babuty D, Lip GY, Fauchier L. Prognosis in patients with atrial fibrillation and CHA2DS2- VASc Score=0 in a community-based cohort study. J Cardiovasc Electrophysiol. 2012;23:708 713. 384. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hem- orrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395 401. 385. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857 867. 386. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007;38:259 263. 387. Hylek EM, Go AS, ChangY, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019 1026. 388. O Donnell M, OczkowskiW, Fang J, Kearon C, Silva J, Bradley C, Guyatt G, Gould L, D Uva C, Kapral M, Silver F; Investigators of the Registry of the Canadian Stroke Network. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5:749 754. 389. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised con- trolled trial. Lancet. 2007;370:493 503. 390. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA; on behalf of the American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advi- sory for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2012;43:3442 3453. 391. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabiga- tran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669 676. 392. Connolly SJ, Ezekowitz MD,Yusuf S, Eikelboom J, Oldgren J, ParekhA, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfa- rin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139 1151. 393. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized con- trolled trials. Arch Intern Med. 2012;172:397 402. 394. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75:800 805. 395. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660 667, W204. 396. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleed- ing with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363 2372. 397. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883 891. 398. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315 322. 399. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moder- ate renal impairment. Eur Heart J. 2011;32:2387 2394. 400. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvu- lar atrial fibrillation: regulatory considerations. N Engl J Med. 2011;365:1557 1559. 401. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS,Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez- Hermosillo A, Dans AL, Munawar M, O Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806 817. 402. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrilla- tion. N Engl J Med. 2011;365:981 992. 403. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11:225 231. 404. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11:503 511. 405. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from theARISTOTLE trial. Eur Heart J. 2012;33:2821 2830. 406. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1 11. 407. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabi- gatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881 883. 408. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98:573 578. 409. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophy- laxis in atrial fibrillation. Circulation. 2011;123:2562 2570. 410. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced throm- bocytopenia: in vitro studies on the interaction of dabigatran, rivaroxa- ban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012;119:1248 1255. 411. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and bayesian meta-analysis and mixed treatment comparison of random- ized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486 1490. 412. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(suppl 1):S141 S145. 413. Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, Wasserman JK, Poon MC, Coutts SB; Canadian PCC Registry (CanPro) Investigators. Poor prognosis in warfarin-associ- ated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43:1812 1817. 414. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903 1912. 415. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S,Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066 2078. 416. Connolly SJ, Eikelboom JW, Ng J, Hirsh J,Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antago- nists are unsuitable. Ann Intern Med. 2011;155:579 586. 417. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297 305. 418. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14 21. 419. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710 1716. 420. Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM, Rosand J. Patient-specific decision-making for warfarin therapy in non- valvular atrial fibrillation: how will screening with genetics and imaging help? Stroke. 2008;39:3308 3315. 421. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hem- orrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689 2696. 422. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, Woodward M, MacMahon S, Neal B; PROGRESS Collaborative Group. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient isch- emic attack. Stroke. 2005;36:2164 2169. 423. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M; Writing Committee of the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke. 2004;35:116 121. 424. Lip GY, Frison L, Grind M; SPORTIF Investigators. Effect of hyper- tension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752 759. 425. Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE; Anticoagulation Forum. Delivery of optimized anticoagu- lant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008;42:979 988. 426. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined antico- agulant-antiplatelet use and major bleeding events in elderly atrial fibril- lation patients. Stroke. 2004;35:2362 2367. 427. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, ChangY, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441 2448. 428. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, JacobsAK,Adams CD,Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of PatientsWithAtrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257 e354. 429. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, ManningWJ;AmericanCollegeofChestPhysicians.Antithrombotictherapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:546S 592S. 430. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, Airaksinen TJ, Niemela M, Vahlberg T, Airaksinen KE. Safety and effi- cacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726 732. 431. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GY. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutane- ous coronary intervention and stent implantation implications for bleed- ing risk and prognosis. J Am Coll Cardiol. 2008;51:818 825. 432. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719 2747. Meschia et al Guidelines for the Primary Prevention of Stroke 3819 433. Francescone S, Halperin JL. Triple therapy or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. J Am Coll Cardiol. 2008;51:826 827. 434. Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting: an expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40:428 436. 435. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O Neill WW, Schaff HV, Whitlow PL, ACC/AHA/SCAI, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guide- lines. J Am Coll Cardiol. 2008;51:172 209. 436. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534 542. 437. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127:720 729. 438. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators.A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825 1833. 439. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA, Khaykin Y, Birnie D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013;173:149 156. 440. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies ofTreatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690 1696. 441. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789 1794. 442. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm con- trol in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834 1840. 443. American College of Cardiology Foundation;American HeartAssociation; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Halperin JL, Le Heuzey J, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guide- lines. Circulation. 2013;127:1916 1926. 444. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation abla- tion in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61:1998 2006. 445. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibril- lation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131 136. 446. Witt BJ, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, Roger VL. The incidence of stroke after myocardial infarction: a meta-analysis. Am J Med. 2006;119:354.e1 354e.9. 447. Osherov AB, Borovik-Raz M, Aronson D, Agmon Y, Kapeliovich M, Kerner A, Grenadier E, Hammerman H, Nikolsky E, Roguin A. Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era. Am Heart J. 2009;157:1074 1080. 448. Solheim S, Seljeflot I, Lunde K, Bjornerheim R, Aakhus S, Forfang K, Arnesen H. Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutane- ous coronary intervention and dual antiplatelet therapy. Am J Cardiol. 2010;106:1197 1200. 449. Schwalm JD, Ahmad M, Salehian O, Eikelboom JW, Natarajan MK. Warfarin after anterior myocardial infarction in current era of dual anti- platelet therapy: a randomized feasibility trial. J Thromb Thrombolysis. 2010;30:127 132. 450. Vaitkus PT, Barnathan ES. Embolic potential, prevention and manage- ment of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993;22:1004 1009. 451. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspi- rin, or both after myocardial infarction. N Engl J Med. 2002;347:969 974. 452. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519 526. 453. O Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG,Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362 e425. 454. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157 164. 455. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of war- farin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119:1616 1624. 456. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS Investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8:428 432. 457. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859 1869. 458. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391 e479. 459. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic ther- apy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e576S e600S. 460. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O Gara PT, O Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation. 2008;118:e523 e661. 461. Barletta GA, Gagliardi R, Benvenuti L, Fantini F. Cerebral ischemic attacks as a complication of aortic and mitral valve prolapse. Stroke. 1985;16:219 223. 462. Gilon D, Buonanno FS, Joffe MM, Leavitt M, Marshall JE, Kistler JP, Levine RA. Lack of evidence of an association between mitral-valve pro- lapse and stroke in young patients. N Engl J Med. 1999;341:8 13. 463. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical outcome of mitral- valve prolapse. N Engl J Med. 1999;341:1 7. 464. Avierinos JF, Brown RD, Foley DA, Nkomo V, Petty GW, Scott C, Enriquez-Sarano M. Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors. Stroke. 2003;34:1339 1344. 465. Benjamin EJ, Plehn JF, D Agostino RB, Belanger AJ, Comai K, Fuller DL, Wolf PA, Levy D. Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med. 1992;327:374 379. 466. Kizer JR, Wiebers DO, Whisnant JP, Galloway JM, Welty TK, Lee ET, Best LG, Resnick HE, Roman MJ, Devereux RB. Mitral annu- lar calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke. 2005;36:2533 2537. 467. Kohsaka S, Jin Z, Rundek T, Boden-Albala B, Homma S, Sacco RL, Di Tullio MR. Impact of mitral annular calcification on cardiovascu- lar events in a multiethnic community: the Northern Manhattan Study. JACC Cardiovasc Imaging. 2008;1:617 623. 468. Jilaihawi H, Chakravarty T, Weiss RE, Fontana GP, Forrester J, Makkar RR. Meta-analysis of complications in aortic valve replacement: com- parison of Medtronic-Corevalve, Edwards-Sapien and surgical aor- tic valve replacement in 8,536 patients. Catheter Cardiovasc Interv. 2012;80:128 138. 469. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, Larsonkeller JJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111 1119. 470. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleed- ing complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635 641. 471. Vahedi K, Amarenco P. Cardiac causes of stroke. Curr Treat Options Neurol. 2000;2:305 318. 472. Stein PD, Alpert JS, Dalen JE, Horstkotte D, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 1998;114(suppl):602S 610S. 473. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, KhderY, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 1214. 474. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345:1318 1330. 475. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabro R, Riberi A, Collart F, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005;112:69 75. 476. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, Mancini L, Sanz O, Sanmartin JV, Stoermann W. Risk of emboliza- tion after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002;39:1489 1495. 477. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, Verhagen DW, Cabell CH; ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086 1094. 478. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160:2781 2787. 479. Cabell CH, Pond KK, Peterson GE, Durack DT, Corey GR, Anderson DJ, Ryan T, LukesAS, Sexton DJ. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J. 2001;142:75 80. 480. Dutta T, Karas MG, Segal AZ, Kizer JR. Yield of transesophageal echo- cardiography for nonbacterial thrombotic endocarditis and other cardiac sources of embolism in cancer patients with cerebral ischemia. Am J Cardiol. 2006;97:894 898. 481. Lechat P, Mas J, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148 1152. 482. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625 2631. 483. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49:797 802. 484. Kizer JR, Devereux RB. Clinical practice: patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353:2361 2372. 485. Gu X, He Y, Li Z, Kontos MC, Paulsen WH, Arrowood JA, Nixon JV. Comparison of frequencies of patent foramen ovale and thoracic aortic atherosclerosis in patients with cryptogenic ischemic stroke undergoing transesophageal echocardiography. Am J Cardiol. 2011;108:1815 1819. 486. Overell J, Bone I, Lees K. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172 1179. 487. O Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC; American Heart Association; American Stroke Association; American College of Cardiology Foundation. Percutaneous device closure of patent fora- men ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from theAmerican Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation. 2009;119:2743 2747. 488. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent fora- men ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262 2268. 489. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, Whisnant JP, Wiebers DO, Covalt JL, Petterson TM, Christianson TJ, AgmonY. Patent foramen ovale: innocent or guilty? Evidence from a pro- spective population-based study. J Am Coll Cardiol. 2006;47:440 445. 490. Goel SS, Tuzcu EM, Shishehbor MH, de Oliveira EI, Borek PP, Krasuski RA, Rodriguez LL, Kapadia SR. Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol. 2009;103:124 129. 491. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345:1740 1746. 492. Di Tullio MR, Jin Z, Russo C, Elkind MS, Rundek T,Yoshita M, DeCarli C, Wright CB, Homma S, Sacco RL. Patent foramen ovale, subclini- cal cerebrovascular disease, and ischemic stroke in a population-based cohort. J Am Coll Cardiol. 2013;62:35 41. 493. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A, Wechsler L; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991 999. 494. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083 1091. 495. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL: RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092 1100. 496. Acebo E, Val-Bernal JF, Gomez-Roman JJ, Revuelta JM. Clinicopathologic study and DNA analysis of 37 cardiac myxomas: a 28-year experience. Chest. 2003;123:1379 1385. 497. Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003;146:404 410. 498. Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol. 1997;80:671 682. 499. Reynen K. Cardiac myxomas. N Engl J Med. 1995;333:1610 1617. 500. Howard RA,Aldea GS, Shapira OM, Kasznica JM, Davidoff R. Papillary fibroelastoma: increasing recognition of a surgical disease. Ann Thorac Surg. 1999;68:1881 1885. 501. Sun JP, Asher CR,Yang XS, Cheng GG, Scalia GM, Massed AG, Griffin BP, Ratliff NB, Stewart WJ, Thomas JD. Clinical and echocardiographic Meschia et al Guidelines for the Primary Prevention of Stroke 3821 characteristics of papillary fibroelastomas: a retrospective and prospec- tive study in 162 patients. Circulation. 2001;103:2687 2693. 502. Ekmektzoglou KA, Samelis GF, Xanthos T. Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeu- tic considerations. J Cardiovasc Med (Hagerstown). 2008;9:769 777. 503. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG.Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331:1474 1479. 504. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S; Patent Foramen Ovale in Cryptogenic Stroke Study Investigators. Aortic arch plaques and risk of recurrent stroke and death. Circulation. 2009;119:2376 2382. 505. Mackensen GB, Ti LK, Phillips-Bute BG, Mathew JP, Newman MF, Grocott HP; Neurologic Outcome Research Group (NORG). Cerebral embolization during cardiac surgery: impact of aortic atheroma burden. Br J Anaesth. 2003;91:656 661. 506. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation. 2006;114:63 75. 507. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke: the French Study of Aortic Plaques in Stroke Group. N Engl J Med. 1996;334:1216 1221. 508. Doty JR, Wilentz RE, Salazar JD, Hruban RH, Cameron DE. Atheroembolism in cardiac surgery. Ann Thorac Surg. 2003;75:1221 1226. 509. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol. 1998;31:134 138. 510. Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the tho- racic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol. 1999;33:1317 1322. 511. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I; NYU Atheroma Group. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90:1320 1325. 512. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, RilesTS, Rosenwasser RH,TaylorAJ;American College of Cardiology Foundation; American Stroke Association; American Association of Neurological Surgeons; American College of Radiology; American Society of Neuroradiology; Congress of Neurological Surgeons; Society of Atherosclerosis Imaging and Prevention; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ASA/ACCF/AHA/ AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011;124:489 532. 513. Endarterectomy for asymptomatic carotid artery stenosis: Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273:1421 1428. 514. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: ran- domised controlled trial. Lancet. 2004;363:1491 1502. 515. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis: the Veterans Affairs Cooperative Study Group. N Engl J Med. 1993;328:221 227. 516. Hass WK, Fields WS, North RR, Kircheff II, Chase NE, Bauer RB. Joint Study of Extracranial Arterial Occlusion, II: arteriography, techniques, sites, and complications. JAMA. 1968;203:961 968. 517. Moore WS, Young B, Baker WH, Robertson JT, Toole JF, Vescera CL, Howard VJ. Surgical results: a justification of the surgeon selection process for the ACAS trial: the ACAS Investigators. J Vasc Surg. 1996;23:323 328. 518. Thiex R, Norbash AM, Frerichs KU. The safety of dedicated-team cath- eter-based diagnostic cerebral angiography in the era of advanced nonin- vasive imaging. AJNR Am J Neuroradiol. 2010;31:230 234. 519. Kaufmann TJ, Huston J 3rd, Mandrekar JN, Schleck CD, Thielen KR, Kallmes DF. Complications of diagnostic cerebral angiography: evalua- tion of 19,826 consecutive patients. Radiology. 2007;243:812 819. 520. Howard G, Chambless LE, Baker WH, Ricotta JJ, Jones AM, O Leary D, Howard VJ, Elliott TJ, Lefkowitz DS, Toole JF. A multicenter validation study of Doppler ultrasound versus angiography. J Stroke Cerebrovasc Dis. 1991;1:166 173. 521. Johnston DC, Goldstein LB. Clinical carotid endarterectomy decision making: noninvasive vascular imaging versus angiography. Neurology. 2001;56:1009 1015. 522. Koelemay MJ, Nederkoorn PJ, Reitsma JB, Majoie CB. Systematic review of computed tomographic angiography for assessment of carotid artery disease. Stroke. 2004;35:2306 2312. 523. Fine-Edelstein JS, Wolf PA, O Leary DH, Poehlman H, Belanger AJ, Kase CS, D Agostino RB. Precursors of extracranial carotid atheroscle- rosis in the Framingham study. Neurology. 1994;44:1046 1050. 524. Weber F. Risk factors for subclinical carotid atherosclerosis in healthy men. Neurology. 2002;59:524 528. 525. Ratchford EV, Jin Z, Di Tullio MR, Salameh MJ, Homma S, Gan R, Boden-Albala B, Sacco RL, Rundek T. Carotid bruit for detection of hemodynamically significant carotid stenosis: the Northern Manhattan Study. Neurol Res. 2009;31:748 752. 526. Rubin MN, Barrett KM, Brott TG, Meschia JF. Asymptomatic carotid stenosis: What we can learn from the next generation of random- ized clinical trials. J R Soc Med Cardiovasc Dis. http://cvd.sagepub. com/content/3/2048004014529419. doi: 10.117/2048004014529419. Accessed May 1, 2014. 527. McPhee JT, Hill JS, Ciocca RG, Messina LM, Eslami MH. Carotid endarterectomy was performed with lower stroke and death rates than carotid artery stenting in the United States in 2003 and 2004. J Vasc Surg. 2007;46:1112 1118. 528. Kresowik TF, Bratzler DW, Kresowik RA, Hendel ME, Grund SL, Brown KR, Nilasena DS. Multistate improvement in process and out- comes of carotid endarterectomy. J Vasc Surg. 2004;39:372 380. 529. Voeks JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC 3rd, Aronow HD, Eskandari MK, Sheffet AJ, Lal BK, Meschia JF, Brott TG; CREST Investigators. Age and outcomes after carotid stenting and endarterectomy: the Carotid Revascularization Endarterectomy Versus Stenting Trial. Stroke. 2011;42:3484 3490. 530. White RA, Sicard GA, Zwolak RM, Sidawy AN, Schermerhorn ML, Shackelton RJ, Siami FS. Society of Vascular Surgery Vascular Registry comparison of carotid artery stenting outcomes for atherosclerotic vs non- atherosclerotic carotid artery disease. J Vasc Surg. 2010;51:1116 1123. 531. Goodney PP, Lucas FL, Likosky DS, Malenka DJ, Fisher ES. Changes in the use of carotid revascularization among the Medicare population. Arch Surg. 2008;143:170 173. 532. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K; Stenting andAngioplasty With Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493 1501. 533. Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE, SAPPHIRE Investigators. Long-term results of carotid stenting versus endarterectomy in high-risk patients. 2008;358:1572 1579. 534. Goldstein LB. New data about stenting versus endarterectomy for symp- tomatic carotid artery stenosis. Curr Treat Options Cardiovasc Med. 2009;11:232 240. 535. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363:11 23. 536. Pawaskar M, Satiani B, Balkrishnan R, Starr JE. Economic evaluation of carotid artery stenting versus carotid endarterectomy for the treatment of carotid artery stenosis. J Am Coll Surg. 2007;205:413 419. 537. McPhee JT, Schanzer A, Messina LM, Eslami MH. Carotid artery stent- ing has increased rates of postprocedure stroke, death, and resource utilization than does carotid endarterectomy in the United States, 2005. J Vasc Surg. 2008;48:1442 1450, 1450.e1. 538. Young KC, Holloway RG, Burgin WS, Benesch CG. A cost-effective- ness analysis of carotid artery stenting compared with endarterectomy. J Stroke Cerebrovasc Dis. 2010;19:404 409. 539. Lal BK, Meschia JF, Brott TG. CREST-2: Guiding treatments for asymp- tomatic carotid disease. Endovascular Today. September 2013:73 76. 540. US Preventive Services Task Force. Screening for carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;147:854 859. 541. Abbott AL. Medical (nonsurgical) intervention alone is now best for pre- vention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke. 2009;40:e573-e583. 542. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsi- lateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke. 2010;41:e11-e17. 543. Woo K, Garg J, Hye RJ, Dilley RB. Contemporary results of carotid end- arterectomy for asymptomatic carotid stenosis. Stroke. 2010;41:975 979. 544. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, Pan H, Peto R, Potter J, Rahimi K, Rau A, Robertson S, Streifler J, Thomas D; Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. 10-Year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010;376:1074 1084. 545. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymp- tomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke. 2004;35:2425 2427. 546. Hirt LS. Progression rate and ipsilateral neurological events in asymp- tomatic carotid stenosis. Stroke. 2014;45:702 706. 547. Adams RJ. Neurologic complications. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principals and Clinical Practice. New York, NY: Raven Press; 1994;599 621. 548. Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease: Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996;97(pt 1):864 870. 549. Ohene-Frempong K,Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288 294. 550. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, ThompsonW, Hess D. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326:605 610. 551. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, McKie K, Figueroa R, Litaker M, Weiner S, Brambilla D. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42:699 704. 552. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5 11. 553. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ; STOP Trial Investigators. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol. 2006;134:333 339. 554. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104:336 339. 555. Ovbiagele B, Adams RJ. Trends in comorbid sickle cell disease among stroke patients. J Neurol Sci. 2012;313:86 91. 556. Jones A, Granger S, Brambilla D, Gallagher D, Vichinsky E, Woods G, Berman B, Roach S, Nichols F, Adams RJ. Can peak systolic velocities be used for prediction of stroke in sickle cell anemia? Pediatr Radiol. 2005;35:66 72. 557. McCarville MB, Goodin GS, Fortner G, Li CS, Smeltzer MP, Adams R, Wang W. Evaluation of a comprehensive transcranial Doppler screen- ing program for children with sickle cell anemia. Pediatr Blood Cancer. 2008;50:818 821. 558. Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial Doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51:647 651. 559. Eckrich MJ, Wang WC, Yang E, Arbogast PG, Morrow A, Dudley JA, Ray WA, Cooper WO. Adherence to transcranial Doppler screening guidelines among children with sickle cell disease. Pediatr Blood Cancer. 2013;60:270 274. 560. National Institutes of Health. Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health; 2002. Publication No. 02-2117. 561. Section on Hematology/Oncology Committee on Genetics; American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526 535. 562. Sampaio Silva G, Vicari P, Figueiredo MS, Filho AC, Valadi N, Massaro AR. Transcranial Doppler in adult patients with sickle cell disease. Cerebrovasc Dis. 2006;21:38 41. 563. Valadi N, Silva GS, Bowman LS, Ramsingh D, Vicari P, Filho AC, Massaro AR, Kutlar A, Nichols FT, Adams RJ. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology. 2006;67:572 574. 564. Kirkham FJ, Hewes DK, Prengler M, Wade A, Lane R, Evans JP. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet. 2001;357:1656 1659. 565. Hollocks MJ, Kok TB, Kirkham FJ, Gavlak J, Inusa BP, DeBaun MR, de Haan M. Nocturnal oxygen desaturation and disordered sleep as a potential factor in executive dysfunction in sickle cell anemia. J Int Neuropsychol Soc. 2012;18:168 173. 566. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139:385 390. 567. DeBaun MR, Gordon M, McKinstry RC, Noetzel DA, White SA, Sarnaik ER, Meier TH, Howard S, Majumdar S, Inusa BPD, Telfer PT, Kirby- Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699 671. 568. Telfer PT, Evanson J, Butler P, Hemmaway C, Abdulla C, Gadong N, Whitmarsh S, Kaya B, Kirkham FJ. Cervical carotid artery dis- ease in sickle cell anemia: clinical and radiological features. Blood. 2011;118:6192 6199. 569. Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P. Long- term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol. 2005;35:242 248. 570. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003;25:622 628. 571. Bernaudin F,Verlhac S, Chevret S, Torres M, Coic L,Arnaud C, Kamdem A, Hau I, Grazia Neonato M, Delacourt C. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant indepen- dent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112:4314 4317. 572. Rees DC, Dick MC, Height SE, O Driscoll S, Pohl KR, Goss DE, Deane CR. A simple index using age, hemoglobin, and aspartate transaminase predicts increased intracerebral blood velocity as measured by transcra- nial Doppler scanning in children with sickle cell anemia. Pediatrics. 2008;121:e1628-e1632. 573. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coic L, Leveille E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galacteros F, Torres M, Kuentz M, Ferry C, Socie G, Reinert P, Delacourt C. Impact of early transcra- nial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117:1130 1140; quiz 1436. 574. Silva CM, Giovani P, Viana MB. High reticulocyte count is an indepen- dent risk factor for cerebrovascular disease in children with sickle cell anemia. Pediatr Blood Cancer. 2011;56:116 121. 575. Savage WJ, Barron-Casella E, Fu Z, Dulloor P, Williams L, Crain BJ, White DA, Jennings JM, Van Eyk JE, Debaun MR, Everett A, Casella JF. Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am J Hematol. 2011;86:427 429. Meschia et al Guidelines for the Primary Prevention of Stroke 3823 576. Asare K, Gee BE, Stiles JK, Wilson NO, Driss A, Quarshie A, Adams RJ, Kutlar A, Hibbert JM. Plasma interleukin-1beta concentration is associ- ated with stroke in sickle cell disease. Cytokine. 2010;49:39 44. 577. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37:435 440. 578. Hoppe C, Klitz W, D Harlingue K, Cheng S, Grow M, Steiner L, Noble J, Adams R, Styles L; Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF(- 308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke. 2007;38:2241 2246. 579. Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, Nagasubramanian R, Mortier NA, Kimble AC, Aygun B, Adams RJ, Helms RW, Ware RE. Genetic predictors for stroke in children with sickle cell anemia. Blood. 2011;117:6681 6684. 580. Thangarajh M, Yang G, Fuchs D, Ponisio MR, McKinstry RC, Jaju A, Noetzel MJ, Casella JF, Barron-Casella E, Hooper WC, Boulet SL, Bean CJ, Pyle ME, Payne AB, Driggers J, Trau HA, Vendt BA, Rodeghier M, DeBaun MR. Magnetic resonance angiography-defined intracranial vas- culopathy is associated with silent cerebral infarcts and glucose-6-phos- phate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol. 2012;159:352 359. 581. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81:1109 1123. 582. Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C, Files B, Adams RJ. Prospective cell phenotype matching in STOP - a multi- center transfusion trial. Paper presented at: 23rd Annual Meeting of the National Sickle Cell Disease Program; March 1999; San Francisco, CA. 583. National Heart, Lung, and Blood Institute. Clinical Alert: NHLBI Stops Study Testing How Long Children with Sickle Cell Anemia Should Have Blood Transfusions to Prevent Stroke. December 5, 2004. http://www. long-children-with-sickle-cell-anemia-should-have-blood-transfusions- to-prevent-stroke.html. Accessed March 19, 2013. 584. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophy- lactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769 2778. 585. Abboud MR, Yim E, Musallam KM, Adams RJ; STOP II Study Investigators. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118:894 898. F, Corazza F, Devalck C, Dresse MF, Hunninck K, Klein A, Le PQ, Loop M, Maes P, Philippet P, Sariban E, Van Geet C, Ferster A. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105:2685 2690. 587. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:894 900. 588. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in chil- dren with sickle cell anemia. Blood. 2007;110:1043 1047. 589. Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC; BABY HUG Investigators. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer. 2012;59:675 678. 590. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, Margueritte G, Bories D, Verlhac S, Esperou H, Coic L, Vernant JP, Gluckman E; SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749 2756. 591. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene- Frempong K, Patience M, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sullivan KM; Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263 272. 592. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d Anglejan-Chatillon J, Bousser M-G. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310:830 833. 593. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123:612 624. 594. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. 595. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of obser- vational studies. BMJ. 2005;330:63. 596. Kurth T, Schurks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009;73:581 588. 597. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardio- vascular disease. Headache. 2010;50:1031 1040. 598. Kurth T, Kase CS, Schurks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2010;341:c3659. 599. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, van Buchem MA, Gudnason V, Launer LJ. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009;301:2563 2570. 600. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI CAMERA study. Brain. 2005;128:2068 2077. 601. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accu- mulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30:129 136. 602. Cavestro C, Richetta L, L Episcopo MR, Pedemonte E, Duca S, Di Pietrantonj C. Anatomical variants of the circle of Willis and brain lesions in migraineurs. Can J Neurol Sci. 2011;38:494 499. 603. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365 391. 604. Martinez-Sanchez P, Martinez-Martinez M, Fuentes B, Cuesta MV, Cuellar-Gamboa L, Idrovo-Freire L, Fernandez-Dominguez J, Diez- Tejedor E. Migraine and hypercoagulable states in ischemic stroke. Cephalalgia. 2011;31:1609 1617. 605. MacClellan L, Giles WH, Cole JW, Wozniak MA, Stern BJ, Mitchell B, Kittner SJ. Probable migraine with visual aura and risk of ischemic stroke: the Stroke Prevention inYoungWomen Study. Stroke. 2007;38:2438 2445. 606. Schurks M, Zee RY, Buring JE, Kurth T. ACE D/I polymor- phism, migraine, and cardiovascular disease in women. Neurology. 2009;72:650 656. 607. Webster M, Chancellor A, Smith H, Swift D, Sharpe D, Bass N, Glasgow G. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11 12. 608. Anzola G, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology. 1999;52:1622 1626. 609. Olesen J, Friberg L, Olsen T, Andersen A, Lassen N, Hansen P, Karle A. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain. 1993;116(pt 1):187 202. 610. Dowson A, Mullen M, Peatfield R, Muir K, Khan A, Wells C, Lipscombe S, Rees T, De Giovanni J, Morrison W, Hildick-Smith D, Elrington G, Hillis W, Malik I, Rickards A. Migraine Intervention With STARFlex Technology (MIST) Trial: a prospective, multicenter, double-blinded, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117:1397 1404. 611. Tobis J. Management of patients with refractory migraine and PFO: is MIST I relevant? Catheter Cardiovasc Interv. 2008;72:60 64. 612. Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL, Homma S. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation. 2008;118:1419 1424. 613. Garg P, Servoss SJ, Wu JC, Bajwa ZH, Selim MH, Dineen A, Kuntz RE, Cook EF, Mauri L. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation. 2010;121:1406 1412. 614. Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology. 2013;40:56 67. 615. Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women s Health Study. Cephalalgia. 2011;31:1106 1115. 616. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 